Enforcement Report - Week of July 19, 2023
Global Pharma Healthcare’s manufacturing site in India has been inspected by the FDA, revealing several stark quality issues.
Global Pharma recalls 50,000 tubes of contaminated eye drops in US: USFDA
FDA Issues Form 483 to Global Pharma Healthcare Ltd.
Enforcement Report - Week of March 29, 2023
Global Pharma Healthcare Issues Voluntary Nationwide Recall of Delsam Pharma Artificial Eye Ointment Due to Possible Microbial Contamination
Global Pharma Healthcare Issues Voluntary Nationwide Recall of Artificial Tears Lubricant Eye Drops Due to Possible Contamination
Global Pharma Healthcare on FDA Import Alert List
SOUTH SAN FRANCISCO, Calif., Dec. 7, 2022 /PRNewswire/ -- Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, and multiple biopharma and academic partners are presenting data from the company's Tapestri® Platform on a range of topics at the 64th Annual American Society of Hematology (ASH) Annual Meeting and Exposition, beginning this weekend in New Orleans, LA. In all, Mission Bio and its partners will share 15 heme-oncology topics highlighting the use of single-cell DNA + protein multi-omics to better understand resistance mechanisms and drivers of relapse, improve identification of Measurable Residual Disease (MRD), and precisely characterize CAR T cell therapies. These include presentations from Servier Pharmaceuticals and researchers at Memorial Sloan Kettering Cancer Center (MSK) that demonstrate Tapestri's® ability to bridge the gap between translational research and precision therapeutics, providing a deeper understanding of the patient journey and unlocking novel therapeutic approaches. These include the following: